| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 27(5); 1995 > Article
Journal of the Korean Cancer Association 1995;27(5): 790-797.
방사선 치료환자에 있어서 치물린 ( Thymulin ) 병용시 면역기능 활성에 관한 연구
안성자, 정웅기, 나병식, 남택근, 조철균, 정상우
Study on the Immunomodulatory Effect of Thymulin in the Patients under Radiotherapy
Sung Ja Ahn, Woong Ki Chung, Byung Sik Nah, Taek Keun Nam, l Gyoon Cho, Sang Woo Juhng
In order to evaluate the effect of Thymulin, which is a thymic extract and known as one of the immunomodulating agents, 20 patients were prescribed the drug, orally one capsule(80 mR) twice a day during the radiation therapy(Thymulin group) and 28 patients were treated with radiotherapy only(RT grouP) randomly. The treatment field was medias- tinum in 29 patients and pelvis in 19, respectively. Age ranged from 36 to 73 years (mean and median; 57) and the male to female ratio was 1.3(27: 21). We evaluated the CBC with D/C, the blood chemistry, the lymphocyte subsets, and serum immunoglobulin level as parameters of the patient's immunological status. Drug intolerance was not observed in any patients. In the Thymulin group, the postirradiation decrease of white blood cell(WBC), lymphocyte, neutrophil, and basophil count was less than that of the RT group, and there was a statistical significance in the difference of the absolute lymphocyte count between two groups. In the peripheral bload lymphocyte subset study, the absolute number of CD4(helper T cell) and CD19(B cel1) were less reduced in the Thymulin group with statistical significance and the change of the other parameters was also less than that of the RT group. In the serum immunoglobulin level, the gostirradiation decrease was less in the Thymulin group and there was a marginal statistical significance in the difference of Ig A between two groups. From the above data, we can reach the conclusion that the combination of Thymulin may reduce the harmful effect of radiation therapy on immunity in cancer patients.
Key words: Immunity, Lymphacyte Subpopulations, Radiotherapy, Thymulin
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
Related article
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2PI